EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,900 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Follow-Up Questions
¿Quién es el CEO de Exact Sciences Corp?
Mr. Kevin Conroy es el Chairman of the Board de Exact Sciences Corp, se unió a la empresa desde 2009.
¿Qué tal es el rendimiento del precio de la acción EXAS?
El precio actual de EXAS es de $65.83, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Exact Sciences Corp?
Exact Sciences Corp pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Exact Sciences Corp?
La capitalización bursátil actual de Exact Sciences Corp es $12.4B
¿Es Exact Sciences Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 24 analistas han realizado calificaciones de análisis para Exact Sciences Corp, incluyendo 13 fuerte compra, 14 compra, 5 mantener, 0 venta, y 13 fuerte venta
